A Phase 3 interventional study of Privosegtor and Methylprednisolone in Optic Neuritis, sponsored by Oculis. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Oculis · Phase 3, Interventional, and Treatment
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
88 studies on the registry are indexed under Optic Neuritis; 16 are open to participants now.
This study's planned enrollment of 210 is above the median of 50 across 58 interventional studies indexed under Optic Neuritis.
Browse Optic Neuritis studies →Oculis is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety
Drug: Privosegtor · Drug: Methylprednisolone
Drug: Methylprednisolone · Other: Placebo
Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days
Methylprednisolone 1 g/day IV for 5 treatment days
0.9% sodium chloride (NaCl) solution IV for 5 treatment days
Proportion of participants achieving at least 15-letter gain from baseline in low contrast visual acuity (LCVA).
Time frame: 3 months
Proportion of participants achieving at least 30-letter gain from baseline in low contrast visual acuity (LCVA).
Time frame: 3 months
Mean change from baseline in low contrast visual acuity (LCVA).
Time frame: 3 months
Mean change from baseline in the ganglion cell - inner plexiform layer (GCIPL) thickness.
Time frame: 3 months
Serum neurofilament light chain (sNfL) mean change from baseline.
Time frame: Through month 3
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oculis